Phillip Clifton-Bligh
Royal North Shore Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Phillip Clifton-Bligh.
Menopause | 2001
Phillip Clifton-Bligh; Rodney J. Baber; Greg Fulcher; Maria-liza Nery; Terry Moreton
ObjectiveThis study was undertaken to evaluate the effects of varying doses of phytoestrogens on lipid and bone metabolism in postmenopausal women. DesignA novel red clover isoflavone preparation (Rimostil) containing genistein, daidzein, formononetin, and biochanin was administered to 46 postmenopausal women in a double-blind protocol after a single-blind placebo phase and followed by a single-blind washout phase. Patients were randomized to receive either 28.5 mg, 57 mg, or 85.5 mg of phytoestrogens daily for a 6-month period. ResultsAt 6 months, the serum high-density lipoprotein cholesterol had risen significantly by 15.7–28.6% with different doses (p = 0.007, p = 0.002, p = 0.027), although the magnitude of the response was independent of the dose used. The serum apolipoprotein B fell significantly by 11.5–17.0% with different doses (p = 0.005, p = 0.043, p = 0.007) and the magnitude of the response was independent of the dose used. The bone mineral density of the proximal radius and ulna rose significantly by 4.1% over 6 months with 57 mg/day (p = 0.002) and by 3.0% with 85.5 mg/day (p = 0.023) of isoflavones. The response with 28.5 mg/day of isoflavones was not significant. There was no significant increase in endometrial thickness with any of the doses of isoflavone used. ConclusionThese results show that the administration of an isoflavone combination extracted from red clover was associated with a significant increase in high-density lipoprotein cholesterol, a significant fall in apolipoprotein B, and a significant increase in the predominantly cortical bone of the proximal radius and ulna after 6 months of treatment. Interpretation of the results is undertaken cautiously because of the absence of a simultaneously studied control group.
Clinical Endocrinology | 1996
Deborah J. Marsh; Deborah McDowall; Valentine J. Hyland; Scott D. Andrew; Margaret Schnitzler; Elizabeth L. Gaskin; David Nevell; Terrence Diamond; Leigh Delbridge; Phillip Clifton-Bligh; Bruce G. Robinson
OBJECTIVE The pentagastrin stimulation test is the traditional test used for the identification of asymptomatic individuals in multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC). The identification of mutations in the RET proto‐oncogene segregating with the disease phenotype in MEN 2A and FMTC families has made it possible to re‐examine the validity of using this test for the identification of affected family members.
Pediatric Pulmonology | 2000
Hugh Allen; Ian G. Thong; Phillip Clifton-Bligh; Susan Holmes; Liza Nery; Karen Byth Wilson
We studied the effect of inhaled corticosteroids on the increase in bone mineral content in prepubertal children with asthma. Forty‐eight asthmatic, prepubertal children receiving either inhaled beclomethasone dipropionate or budesonide were evaluated. Nine children of similar age not receiving inhaled steroids served as controls. The average age of corticosteroid‐treated children was 7.8 ± 2.4 years, and of control children, 8.4 ± 2.1 years (NS). The average dose of inhaled corticosteroids in the treated children was 0.67 ± 0.48 mg/m2/day, and they were followed over a 9–20‐month period.
Journal of Paediatrics and Child Health | 1996
Cronin Cs; T. S. Reeve; Bruce G. Robinson; Phillip Clifton-Bligh; Ana I. Guinea; Leigh Delbridge
Objective: The aim of this study was to determine the nature of the presentation and pathology of primary hyperparathyroidism in children and adolescents and to compare these findings with adults.
Experimental Biology and Medicine | 2007
Suzanne Niblett; Katrina King; R. Hugh Dunstan; Phillip Clifton-Bligh; Leigh Hoskin; Timothy K. Roberts; Greg Fulcher; Neil R. McGregor; Julie C. Dunsmore; Henry L. Butt; Iven Klineberg; Tony Rothkirch
Patients with chronic fatigue syndrome (CFS) have a broad and variable spectrum of signs and symptoms with variable onsets. This report outlines the results of a single-blind, cross-sectional research project that extensively investigated a large cohort of 100 CFS patients and 82 nonfatigued control subjects with the aim of performing a case-control evaluation of alterations in standard blood parameters and urinary amino and organic acid excretion profiles. Blood biochemistry and full blood counts were unremarkable and fell within normal laboratory ranges. However, the case-control comparison of the blood cell data revealed that CFS patients had a significant decrease in red cell distribution width and increases in mean platelet volume, neutrophil counts, and the neutrophil-lymphocyte ratio. Evaluation of the urine excretion parameters also revealed a number of anomalies. The overnight urine output and rate of amino acid excretion were both reduced in the CFS group (P < 0.01). Significant decreases in the urinary excretion of asparagine (P < 0.0001), phenylalanine (P < 0.003), the branch chain amino acids (P < 0.005), and succinic acid (P < 0.0001), as well as increases in 3-methylhistidine (P < 0.05) and tyrosine (P < 0.05) were observed. It was concluded that the urinary excretion and blood parameters data supported the hypothesis that alterations in physiologic homeostasis exist in CFS patients.
Australian & New Zealand Journal of Obstetrics & Gynaecology | 2000
Jenny E. Gunton; Aidan McElduff; M Sulway; J. N. Stiel; Ian Kelso; S Boyce; Gregory R. Fulcher; Bruce G. Robinson; Phillip Clifton-Bligh; Errol Wilmshurst
Pregestational diabetes mellitus (DM) is associated with adverse fetal and maternal outcomes. Studies suggest that optimal control of diabetes before and during pregnancy minimises these risks. There are few recent reviews of outcomes of pregnancies complicated by DM in Australia.
Annals of Internal Medicine | 1979
Solomon Posen; Phillip Clifton-Bligh; Thomas Cromer
Excerpt Patients with hypoparathyroidism develop radiologic opacities in the basal ganglia and other parts of the brain (1, 2). The condition is believed to be relatively rare in surgical hypoparat...
European Journal of Clinical Nutrition | 2015
Phillip Clifton-Bligh; Nery Ml; Roderick J. Clifton-Bligh; Visvalingam S; Gregory R. Fulcher; Karen Byth; Rod Baber
Background:Although postmenopausal combined hormone replacement therapy reduces the risk of hip fracture, long-term use may be associated with an increased risk of breast cancer, and in women more than 10 years after menopause it is associated with an increased risk of cardiovascular disease. Isoflavones, because of preferential binding to estrogen receptor beta, may retain the beneficial effects on bone but lessen the adverse effects on the breast.Objective:The objective of this study was to study the effects of an isoflavone obtained from red clover (Rimostil) on bone mineral density, and on low-density lipoprotein (LDL) cholesterol.Design:In a double-blind, randomized, placebo-controlled trial, 50 mg of Rimostil was given to women who were menopausal for at least 1 year. Bone mineral density of the spine, femoral neck and forearm and serum LDL cholesterol were measured at baseline and at 6-month intervals. The duration of follow-up was 2 years.Results:There was no beneficial effect of Rimostil on bone density at any site. There was a 12% fall in serum LDL cholesterol in the Rimostil-treated arm, which was significantly greater than the 2% drop seen in the control arm (P=0.005).
Internal Medicine Journal | 2004
S. S. Y. Chan; L. M. Nery; Aidan McElduff; Errol Wilmshurst; Gregory R. Fulcher; Bruce G. Robinson; J. N. Stiel; Jenny E. Gunton; Phillip Clifton-Bligh
Abstract
Anz Journal of Surgery | 2010
Deepak Abraham; Leigh Delbridge; Roderick J. Clifton-Bligh; Phillip Clifton-Bligh; Simon Grodski; Bruce G. Robinson; Marinella Messina; Stan B. Sidhu
Background: Carcinoembryonic antigen (CEA) is a tumour marker commonly associated with gastrointestinal malignancy. Patients presenting with an elevated CEA will therefore often undergo extensive investigations in order to elucidate an underlying gastrointestinal malignancy that may not be clinically apparent. However the GI tract is not the only source of CEA elevation.